Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-671

By ecancer FEATURING Luis Raez
By ecancer FEATURING Luis Raez
February 23, 2024
Disclaimer: On March 1, 2024, The FDA has approved amivantamab-vmjw (RYBREVANT®) plus carboplatin and pemetrexed for the frontline treatment of patients with locally advanced or mNSCLC harboring EGFR exon 20 insertion mutations, as detected by an FDA-approved test.
1 Comment
Login to view comments. Click here to Login